C Folgueira1,2,3, E Sanchez-Rebordelo2,3, S Barja-Fernandez1,2,4, R Leis4, S Tovar2,3, F F Casanueva2,5, C Dieguez2,3, R Nogueiras6,7, L M Seoane8,9. 1. Grupo Fisiopatología Endocrina, Laboratorio 14, Instituto de Investigación Sanitaria de Santiago de Compostela, Complexo Hospitalario Universitario de Santiago (CHUS/SERGAS), Universidad de Santiago de Compostela (USC), Travesía da Choupana s/n, 15706, Santiago de Compostela, Spain. 2. CIBER Fisiopatología Obesidad y Nutrición, Instituto de Salud Carlos III, Universidad de Santiago de Compostela (USC), Santiago de Compostela, Spain. 3. Department of Physiology, Research Centre of Molecular Medicine and Chronic Diseases (CIMUS), Instituto de Investigación Sanitaria de Santiago de Compostela, Complexo Hospitalario Universitario de Santiago (CHUS/SERGAS), Universidad de Santiago de Compostela (USC), Santiago de Compostela, Spain. 4. Pediatric Department, Instituto de Investigación Sanitaria de Santiago de Compostela, Complexo Hospitalario Universitario de Santiago (CHUS/SERGAS), Universidad de Santiago de Compostela (USC), Santiago de Compostela, Spain. 5. Laboratorio de Endocrinología Molecular y Celular, Instituto de Investigación Sanitaria de Santiago de Compostela, Complexo Hospitalario Universitario de Santiago (CHUS/SERGAS), Universidad de Santiago de Compostela (USC), Santiago de Compostela, Spain. 6. CIBER Fisiopatología Obesidad y Nutrición, Instituto de Salud Carlos III, Universidad de Santiago de Compostela (USC), Santiago de Compostela, Spain. ruben.nogueiras@usc.es. 7. Department of Physiology, Research Centre of Molecular Medicine and Chronic Diseases (CIMUS), Instituto de Investigación Sanitaria de Santiago de Compostela, Complexo Hospitalario Universitario de Santiago (CHUS/SERGAS), Universidad de Santiago de Compostela (USC), Santiago de Compostela, Spain. ruben.nogueiras@usc.es. 8. Grupo Fisiopatología Endocrina, Laboratorio 14, Instituto de Investigación Sanitaria de Santiago de Compostela, Complexo Hospitalario Universitario de Santiago (CHUS/SERGAS), Universidad de Santiago de Compostela (USC), Travesía da Choupana s/n, 15706, Santiago de Compostela, Spain. luisamaria.seoane@usc.es. 9. CIBER Fisiopatología Obesidad y Nutrición, Instituto de Salud Carlos III, Universidad de Santiago de Compostela (USC), Santiago de Compostela, Spain. luisamaria.seoane@usc.es.
Abstract
PURPOSE: Uroguanylin (UGN) is a 16 amino acid peptide produced mainly by intestinal epithelial cells. Nutrients intake increases circulating levels of prouroguanylin that is processed and converted to UGN to activate the guanylyl cyclase 2C receptor (GUCY2C). Given that the UGN-GUCY2C system has been proposed as a novel gut-brain endocrine axis regulating energy balance, the aim of the present study was to investigate the regulation of UGN protein levels in duodenum and circulating levels in lean and obese mice under different nutritional conditions and its potential interaction with leptin. METHODS: Swiss, C57BL/6 wild-type and ob/ob male adult mice under different nutritional conditions were used: fed ad libitum standard diet (control); 48 h fasting (fasted); 48 h fasting followed by 24 h of feeding (refed); and fed high-fat diet (45 %) during 10 weeks. In addition, peripheral leptin administration was performed. Intestinal uroguanylin expression was studied by Western blot analysis; plasma levels were measured by ELISA. RESULTS: Food deprivation significantly reduced plasma UGN levels, which were correlated with the lower protein levels of UGN in duodenum. These effects were reverted after refeeding and leptin challenge. Consistently, in ob/ob mice UGN expression was decreased, whereas leptin treatment up-regulated UGN levels in duodenum in these genetically modified mice compared to WT. Diet-induced obese mice displayed increased UGN levels in intestine and plasma in comparison with lean mice. CONCLUSIONS: Our findings suggest that UGN levels are correlated with energy balance status and that the regulation of UGN by nutritional status is leptin-dependent.
PURPOSE:Uroguanylin (UGN) is a 16 amino acid peptide produced mainly by intestinal epithelial cells. Nutrients intake increases circulating levels of prouroguanylin that is processed and converted to UGN to activate the guanylyl cyclase 2C receptor (GUCY2C). Given that the UGN-GUCY2C system has been proposed as a novel gut-brain endocrine axis regulating energy balance, the aim of the present study was to investigate the regulation of UGN protein levels in duodenum and circulating levels in lean and obesemice under different nutritional conditions and its potential interaction with leptin. METHODS: Swiss, C57BL/6 wild-type and ob/ob male adult mice under different nutritional conditions were used: fed ad libitum standard diet (control); 48 h fasting (fasted); 48 h fasting followed by 24 h of feeding (refed); and fed high-fat diet (45 %) during 10 weeks. In addition, peripheral leptin administration was performed. Intestinal uroguanylin expression was studied by Western blot analysis; plasma levels were measured by ELISA. RESULTS: Food deprivation significantly reduced plasma UGN levels, which were correlated with the lower protein levels of UGN in duodenum. These effects were reverted after refeeding and leptin challenge. Consistently, in ob/ob miceUGN expression was decreased, whereas leptin treatment up-regulated UGN levels in duodenum in these genetically modified mice compared to WT. Diet-induced obesemice displayed increased UGN levels in intestine and plasma in comparison with lean mice. CONCLUSIONS: Our findings suggest that UGN levels are correlated with energy balance status and that the regulation of UGN by nutritional status is leptin-dependent.
Authors: Michael A Valentino; Jieru E Lin; Adam E Snook; Peng Li; Gilbert W Kim; Glen Marszalowicz; Michael S Magee; Terry Hyslop; Stephanie Schulz; Scott A Waldman Journal: J Clin Invest Date: 2011-08-25 Impact factor: 14.808
Authors: S L Carrithers; M T Barber; S Biswas; S J Parkinson; P K Park; S D Goldstein; S A Waldman Journal: Proc Natl Acad Sci U S A Date: 1996-12-10 Impact factor: 11.205
Authors: Manuel D Gahete; David Rincón-Fernández; Alicia Villa-Osaba; Daniel Hormaechea-Agulla; Alejandro Ibáñez-Costa; Antonio J Martínez-Fuentes; Francisco Gracia-Navarro; Justo P Castaño; Raúl M Luque Journal: J Endocrinol Date: 2013-12-02 Impact factor: 4.286
Authors: A Rodríguez; J Gómez-Ambrosi; V Catalán; S Ezquerro; L Méndez-Giménez; S Becerril; P Ibáñez; N Vila; M A Margall; R Moncada; V Valentí; C Silva; J Salvador; G Frühbeck Journal: Int J Obes (Lond) Date: 2016-04-25 Impact factor: 5.095
Authors: D J Merlino; J R Barton; B A Charsar; M D Byrne; J A Rappaport; R J Smeyne; A C Lepore; A E Snook; S A Waldman Journal: Brain Struct Funct Date: 2019-09-04 Impact factor: 3.270
Authors: Matthew D Di Guglielmo; Dalal Tonb; Zhaoping He; Adebowale Adeyemi; Kenneth L van Golen Journal: J Pediatr Gastroenterol Nutr Date: 2018-03 Impact factor: 2.839
Authors: Erik S Blomain; Dante J Merlino; Amanda M Pattison; Adam E Snook; Scott A Waldman Journal: Mol Pharmacol Date: 2016-06-01 Impact factor: 4.436
Authors: Nikola Habek; Marina Dobrivojević Radmilović; Milan Kordić; Katarina Ilić; Sandra Grgić; Vladimir Farkaš; Robert Bagarić; Siniša Škokić; Alfred Švarc; Aleksandra Dugandžić Journal: Pflugers Arch Date: 2020-01-15 Impact factor: 3.657